While the coronavirus has impacted millions of Americans across the United States, it has hit the elderly population particularly hard. In fact, more than 40 percent of coronavirus deaths in the U.S. have been linked to long-term care facilities, according to a New York Times survey. In an effort to bring those numbers down, pharmaceutical company Eli Lilly, in partnership with the National Institutes of Health (NIH), has just launched a late-stage antibody treatment trial focusing on residents and staff at nursing homes.
"COVID-19 has had a devastating impact on nursing home residents," Lilly's chief scientific officer Daniel Skovronsky said in a statement. "We're working as fast as we can to create medicines that might stop the spread of the virus to these vulnerable individuals."
The trial is expected to enroll up to 2,400 participants who live or work at a facility and have recently been diagnosed with the disease. The trial will evaluate the safety and success of using LY-CoV555, a potent, neutralizing antibody that works against the spike protein of the novel coronavirus. The trial will look at whether a single dose of the antibody treatment reduces the rate of infection over four weeks as well as symptoms over eight weeks.
"The importance of these kinds of therapies for people like the elderly or immunocompromised is that they can provide the hope and the safety net that these people really need right now," said Andrew Adams, vice president of new therapeutic modalities & COVID-19 research at Eli Lilly, who is overseeing the trial. "I think people in those populations are really desperate and looking for something to help with the coronavirus."
Eli Lilly is taking its trial on the road with customized mobile research units that can travel directly to areas that are experiencing outbreaks.
"This is an interesting solution, to bring the medicine to these vulnerable patients," said Adams. "This lets us be flexible and move these trials around the country, tracking these trials as we come across them."
Adams said he is hoping Eli Lilly will have results on the efficacy of these antibodies in the fourth quarter of this year. Even if successful, though, he says research for a vaccine needs to continue.
"These have to be thought of as more of a bridge, where a vaccine provides long-term protection in terms of years of immunity, where we will provide hopefully in the range of months with these types of treatments. We hope this to be a short-term bridge to the long-term effective vaccination," he said.
Stan Farnsworth, chief marketing officer at PulseForge, joined Cheddar to talk about his company's debut at CES 2022 and how it plans to innovate the sustainable tech manufacturing space. PulseForge is bringing a new approach to industrial thermal processing, which contributes to 30 percent of global greenhouse gas emissions, according to Farnsworth. "By using 85 percent less energy in the processing of materials through a variety of manufacturing processes, we can make a direct impact in reducing carbon output and reducing carbon footprint associated with manufacturing," he said.
The U.S. will be implementing a vaccine mandate for all people entering through its land borders, removing exemptions for "essential" travelers such as truckers, students, and business people. While the Canadian Trucking Alliance argues that the new, stricter rule might exacerbate ongoing auto supply chain issues, some health experts see the potential for helping curb the ongoing pandemic. Anthony Santella, a professor of health administration at the University of New Haven, joined Cheddar to give his take on the updated border crossing restriction. "We can't just focus on one type of travel. We need to ensure that it's clear and consistent across all types of travel," Santella said.
Mona Zhang, states cannabis policy reporter at POLITICO Pro joins Cheddar News to discuss major factors that caused Canada's retail marijuana sales to drop last year.
To encourage and inspire young women to pursue careers in STEAM, or science, technology, engineering, arts, and math, Space VIP has officially launched its New York Space Prize Challenge. Young women enrolled in the public school system within New York's five boroughs and are between the ages of 15 to 18 are welcomed to participate. Executive Director of Space Prize, Kim Macharia, joined Cheddar to discuss more.
According to a recent report from NASA and NOAA, the last eight years have been the eight hottest years on record. Director of NASA's Goddard Institute For Space Studies Gavin Schmidt, joined Cheddar to discuss more.
Aditi Mayer, a climate justice activist joins Cheddar News to discuss her partnership with DoSomething.org and how a new PSA is working to shine a light on environmental racism.
The drama surrounding tennis star Novak Djokovic continues after he was deported from Australia over the weekend due to the nation's COVID-19 vaccine requirements. Djokovic was forced to leave the country on the eve of what was to be his first match in defense of his Australian Open title after three judges ruled in favor of his removal and revealed their reasoning for doing so. Adding to his woes, a law recently passed in France is putting his chances of defending his French Open title in jeopardy. The director of Marist's Center for Sports Communication, Jane McManus, joined Cheddar to discuss the ongoing fallout.
On this episode of Cheddar Innovates: Vrai CEO discusses the process of creating lab grown diamonds, Entrupy CEO breaks down how the app uses artificial intelligence to analyze authenticity for luxury goods and sneakers; A look at Curiosity Stream's 'Red Elvis.'
The Department of Agriculture has officially unveiled its plan to fight catastrophic wildfires that have devastated parts of the West in the last few years. The department, along with the Forest Service will work to significantly increase fuels and forest health treatments to address the escalating crisis of wildfire danger. Executive Editor of Cipher, a publication by Breakthrough Energy, Amy Harder, joined Cheddar to discuss more.
Brainsway, the medical device company that developed deep TMS, has been conducting clinical trials of the treatment in various psychiatric, neurological, and addiction disorders. Their most recent research suggests that deep TMS is an effective treatment for OCD. Christopher Von Jako, president and chief executive officer of Brainsway, joins Cheddar News to discuss.
